Lannett Company Inc (LCI.N) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lannett Company Inc receives FDA approval for Oxycodone Hydrochloride Capsules 5 mg


Monday, 4 Aug 2014 07:53am EDT 

Lannett Company Inc:Receives approval from U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride Capsules, 5 mg.Says therapeutic equivalent to reference listed drug, Oxycodone Hydrochloride Capsules, 5 mg, of Lehigh Valley Technologies, Inc.According to IMS, for year ended June 2014 total sales of Oxycodone Hydrochloride Capsules, 5 mg, at Average Wholesale Price (AWP) were about $7.1 mln.The company expects to commence shipping the product in the coming months.